Galapagos showcases innovative approach in hematological
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic...
Source: globenewswire.com
📰 Eva Santermans News
Eva Santermans News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eva Santermans. Real-time updates on events, politics, business and more.
Galapagos NV: Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib
Source: finanznachrichten.de
Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Investegate announcements from Galapagos NV, Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Source: investegate.co.uk
Galapagos NV: Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
Five presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityNew analyses will be presented from the SELECTION data set on prediction of response and remission
Source: finanznachrichten.de
Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
Investegate announcements from Galapagos NV, Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
Source: investegate.co.uk